Cargando…

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY

Detalles Bibliográficos
Autores principales:	Carpenedo, Monica, Broome, Catherine M, Mcdonald, Vickie, Miyakawa, Yoshitaka, Kuter, David, Al-Samkari, Hanny, Bussel, James, Matthijssens, Filip, Hultberg, Anna, Ayguasanosa Dachs, Jaume, De Beuf, Kristof, Rodeghiero, Francesco, Michel, Marc, Newland, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428374/ http://dx.doi.org/10.1097/01.HS9.0000968120.02996.d3

Ejemplares similares

Efgartigimod alfa for the treatment of primary immune thrombocytopenia
por: Broome, Catherine
Publicado: (2023)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
por: Newland, Adrian C., et al.
Publicado: (2019)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
por: Cheloff, Abraham Z., et al.
Publicado: (2020)

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
por: Knoebl, P., et al.
Publicado: (2022)

Efgartigimod: First Approval
por: Heo, Young-A
Publicado: (2022)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Correction to: Efgartigimod: First Approval
por: Heo, Young-A
Publicado: (2022)

COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic
por: Al-Samkari, Hanny
Publicado: (2023)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
por: Carpenedo, Monica, et al.
Publicado: (2023)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumor s and hematologic malignancies
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials
por: Kuter, David J., et al.
Publicado: (2020)

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
por: Lee, Eun-Ju, et al.
Publicado: (2021)

Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
por: Kritharis, Athena, et al.
Publicado: (2018)

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice
por: Song, Fei, et al.
Publicado: (2021)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
por: Kuter, David J., et al.
Publicado: (2019)

Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association
por: Rodeghiero, Francesco
Publicado: (2021)

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Management of thrombocytopenia
por: Izak, Marina, et al.
Publicado: (2014)

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
por: Napolitano, Mariasanta, et al.
Publicado: (2023)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

The spleen in immune thrombocytopenia
por: Geyer, Julia T., et al.
Publicado: (2018)

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
por: Broome, Catherine M., et al.
Publicado: (2022)

Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia
por: Bloom, Patricia P., et al.
Publicado: (2020)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
por: Kuter, David J.
Publicado: (2022)

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
por: Röth, Alexander, et al.
Publicado: (2022)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023)

Current Management of Primary Immune Thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2015)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?
por: Bussel, James, et al.
Publicado: (2019)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
por: Tsykunova, G., et al.
Publicado: (2022)

The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
por: Al-Samkari, Hanny, et al.
Publicado: (2018)

Thrombocytopenia in Virus Infections
por: Raadsen, Matthijs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nbs4hu0err888k0ujluhqgb675